Iantrek Inc, a medical technology company focused on bio-interventional approaches for chronic eye diseases, has named Adam Szaronos as its new chief executive officer. Szaronos succeeds company founder Sean Ianchulev, MD, MPH, who will continue to serve as chairman of the board and chief medical officer, the company reported in a press release.

Dr. Ianchulev stated that the leadership transition aligns with Iantrek’s shift from technology development to commercialization. “We went through an extensive search process which culminated in Adam’s appointment. I could not be more confident in our ability to execute given all the talent of our leadership team and our entire organization,” he said.

Szaronos has nearly 20 years of experience in the ophthalmic industry, including leadership roles in pharmaceutical, medical device, and medical technology sectors. He has contributed to the launch of over 50 technologies spanning cataract, refractive, and vitreoretinal surgery, diagnostics, and digital health. Most recently, he served as CEO and president of Trukera Medical, where he led a strategic turnaround that resulted in the company’s acquisition by Bausch + Lomb. He previously spent 14 years at Alcon in sales, marketing, and strategic leadership roles.

Iantrek’s first two surgical glaucoma products, AlloFlo and C-Rex, are in a controlled release phase in the US market, with a full commercial launch planned for later this year. The company is also developing additional bio-interventional and micro-interventional technologies, with product launches anticipated through 2026. GP